Formulations for treatment with glucosinolates
The application relates to topical formulations comprising a phase II enzyme inducer precursor and an activating agent. Methods for producing and using the topical formulations are also provided.
1. A dispensing apparatus comprising a formulation comprising:
(a) at least one phase II enzyme inducer precursor and
(b) at least one activating agent,
wherein contact between said precursor and agent is substantially reduced during storage and the formulation is a topical formulation;
wherein the precursor and the agent are each separately encapsulated in a carrier; and wherein the carrier is a micelle, a liposome, or a microsphere.
2. The dispensing apparatus of claim 1 , wherein said precursor is a glucosinolate.
3. The dispensing apparatus of claim 2 , wherein said glucosinolate is glucoraphanin.
4. The dispensing apparatus of claim 1 , wherein said agent is a myrosinase.
5. The dispensing apparatus of claim 1 , wherein said inducer is an isothiocyanate.
6. The dispensing apparatus of claim 5 , wherein said isothiocyanate is sulforaphane.
7. The dispensing apparatus of claim 1 , wherein said precursor and agent are placed in a thixotropic medium.
8. The dispensing apparatus of claim 1 , wherein the formulation is selected from the group consisting of a cream, a lotion, a gel, an ointment, a paste, and an aerosol spray.
9. The dispensing apparatus of claim 1 , wherein the formulation is sterile at least prior to a first use of the formulation.
10. The dispensing apparatus of claim 1 , further comprising an antimicrobial composition.
11. The dispensing apparatus of claim 10 , wherein the antimicrobial composition comprises benzyl alcohol.
12. A method of making a formulation comprising:
(a) providing at least one phase II enzyme inducer precursor;
(b) providing at least one activating agent;
(c) providing a medium; and
(d) forming the formulation by including elements (a), (b), and (c) therein,
wherein the formulation is selected from the group consisting of a topical formulation, a pill, a beverage, and a food;
wherein the precursor and the agent are each separately encapsulated in a carrier; and wherein the carrier is a micelle, a liposome, or a microsphere.
13. The method of claim 12 , wherein said precursor is a glucosinolate.
14. The method of claim 12 , wherein said activating agent is a myrosinase.
15. The method of claim 12 , wherein the topical formulation is a cream, a lotion, a gel, an ointment, a paste, or an aerosol.
16. The method of claim 12 , further providing an antimicrobial composition.
17. The method of claim 12 , wherein the medium is a thixotropic material.
18. A method of treating skin ailments comprising:
(a) providing a topical formulation; and
(b) applying the formulation to the surface of skin with the dispensing apparatus of claim 1 .
19. The method of claim 12 , wherein the topical formulation comprises at least one phase II enzyme inducer precursor and at least one activating agent such that contact between said precursor and said agent is substantially reduced.
20. The method of claim 19 , wherein said precursor and said agent are each encapsulated in a carrier selected from the group comprising a micelle, a liposome, and a microsphere.
21. The method of claim 20 , wherein the topical formulation is a cream, a lotion, a gel, an ointment, a paste, or an aerosol spray.
22. A method of treating skin ailments comprising:
(a) providing a topical formulation in a container, wherein the topical formulation comprises at least one phase II enzyme inducer precursor and at least one activating agent, wherein contact between the precursor and agent is substantially reduced;
(b) mixing the precursor and agent together to create a mixture; and
(c) applying the mixture to the surface of skin.
23. The method of claim 22 , wherein the container is selected from the group comprising a syringe, a tube, and a dispensing apparatus.
24. The method of claim 22 , further comprising a medium selected from the group comprising a cream, a lotion, a gel, an ointment, and a paste.
25. The method of claim 22 , wherein said precursor and said agent are encapsulated in a carrier selected from the group comprising a micelle, a liposome, and a microsphere.
26. The method of claim 25 , wherein step (b) comprises providing pressure or stress onto said medium such that said carrier is not broken or does not release said precursor or activating agent.
27. A method of treating skin cancer comprising:
(a) providing a topical formulation comprising at least one phase II enzyme inducer precursor and at least one activating agent, wherein the precursor and agent are each encapsulated in a carrier such that contact between said precursor and said agent is substantially reduced;
(b) mixing the carriers containing said precursor and said agent together to create a mixture; and
(c) applying the mixture to the surface of skin.
28. The method of claim 27 , wherein said precursor is a glucosinolate.
29. The method of claim 27 , wherein said agent is a myrosinase.
30. The method of claim 27 , wherein said phase II enzyme is an isothiocyanate.
31. The method of claim 27 , wherein said topical formulation further comprises a dermal penetration-enhancing compound.
32. The method of claim 27 , wherein the method of treating comprises applying the mixture to the surface of skin after skin damage.
33. The method of claim 27 , wherein the method of treating comprises applying the mixture to the surface of skin before skin damage.